表紙
市場調査レポート - 217342

Cariprazine:市場分析および予測

Cariprazine - Analysis and Forecasts from 2013 to 2020

発行 GlobalData
出版日 ページ情報 英文 26 Pages
価格
Cariprazine:市場分析および予測 Cariprazine - Analysis and Forecasts from 2013 to 2020
出版日: 2011年07月28日 ページ情報: 英文 26 Pages
概要

当レポートでは、統合失調症治療薬である Cariprazine のパイプライン分析および市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争を盛り込んで、概略以下の構成でお届けします。

目次

1. 目次

  • 1.1 表一覧
  • 1.2 図一覧

2. イントロダクション

  • 2.1 統合失調症
  • 2.2 症状
  • 2.3 統合失調症 市場
  • 2.4 疫学
  • 2.5 病因論
    • 2.5.1 遺伝的要因
    • 2.5.2 環境的要因
    • 2.5.3 脳構造の異常
  • 2.6 GlobalData レポートガイダンス

3. 統合失調症

  • 3.1 統合失調症 市場
  • 3.2 統合失調症 市場 予測およびCAGR
  • 3.3 ドライバー; 統合失調症 治療薬市場
    • 3.3.1 特許期間の終了; 主要な上市薬
    • 3.3.2 患者プールの増加
    • 3.3.3 高い処方率
    • 3.3.4 患者の薬剤服用遵守率の低さ
    • 3.3.5 高いアンメット・ニーズ

    4. 分類; 統合失調症

    • 4.1 発症年齢 統合失調症
      • 4.1.1 小児 / 青年期 / 幼年期 統合失調症
      • 4.1.2 成人の統合失調症
    • 4.2 関連症状
      • 4.2.1 妄想型統合失調症
      • 4.2.2 破瓜型統合失調症
      • 4.2.3 緊張型統合失調症
      • 4.2.4 残遺型統合失調症
      • 4.2.5 未分化障害

    5. 治療法; 統合失調症

    • 5.1 危機解決チーム (CRT)
    • 5.2 自発的および強制的滞留
    • 5.3 抗精神病薬
      • 5.3.1 定型抗精神病薬
      • 5.3.2 非定型抗精神病薬
      • 5.3.3 死亡率の増加 − 認知症関連の精神病を患う老年患者

    6. Cariprazine

    • 6.1 イントロダクション
    • 6.2 作用機序
    • 6.3 臨床研究
    • 6.4 Cariprazine 新薬開発状況
    • 6.5 売上影響因子; Cariprazine
      • 6.5.1 ユニークな受容体結合特性
      • 6.5.2 高い競争率
      • 6.5.3 コラボレーション
      • 6.5.4 無名の存在 − EU
    • 6.6 医薬品評価
      • 6.6.1 薬物のリスク・ベネフィット評価
      • 6.6.2 競争の激しさ
    • 6.7 売上 予測
      • 6.7.1 標的患者プール; Cariprazine
      • 6.7.2 投薬
      • 6.7.3 市場浸透率
      • 6.7.4 治療の年間コスト;
      • 6.7.5 売上予測; Cariprazine

    7. 統合失調症 市場: 付録

    • 7.1 市場定義
    • 7.2 略語
    • 7.3 調査方法
    • 7.4 治療薬の売上予想モデル
    • 7.5 お問い合わせ
    • 7.6 免責事項
    • 7.7 情報ソース

    表一覧

    • 表 1: Cariprazine, 第二相 臨床試験 結果
    • 表 2: Cariprazine, 新薬開発状況
    • 表 3: 薬物のリスク・ベネフィット評価; Cariprazine
    • 表 4: 競合; Cariprazine
    • 表 5: Cariprazine, 統合失調症, 世界市場 売上 予測 ($m)
    • 表 6: Cariprazine, 統合失調症, 米国, 売上 予測 ($m)
    • 表 7: Cariprazine, 統合失調症, 日本, 売上 予測 ($m)

    図一覧

    • 図 1: 進行のリスク; 統合失調症
    • 図 2: 進行の環境的要因; 統合失調症
    • 図 3: 統合失調症, 世界市場 市場規模予測 ($bn)
    • 図 4: 分類; 統合失調症 (発症年齢ベース)
    • 図 5: PANSS スコアの低下; 非定型抗精神病薬
    • 図 6: 薬物モデルダイアグラム; Cariprazine
    • 図 7: Cariprazine, 統合失調症, 世界市場 売上 予測 ($m)
    • 図 8: Cariprazine, 統合失調症, 米国, 売上 予測 ($m)
    • 図 9: Cariprazine, 統合失調症, 日本, 売上 予測 ($m)
    • 図 10: Cariprazine, 統合失調症, 世界市場 売上分布予測 − 主要国 (%)

  • 目次

    Abstract

    Summary

    GlobalData's pharmaceuticals report, "Cariprazine - Analysis and Forecasts from 2013 to 2020" provides Cariprazine sales estimates for US and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

    Scope

    • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
    • Analysis and review of Cariprazine including sales data
    • Qualitative and quantitative assessment of market space
    • Analysis of the trends, drivers and restraints shaping and defining the markets
    • In-depth analysis of Cariprazine including efficacy, safety, pricing and other details which influence its sales potential
    • Detailed sales forecast for 2013-2020 for Cariprazine in the US and Japan

    Reasons to buy

    • Understand and capitalize by identifying products that are most likely to ensure a robust return
    • Stay ahead of competition by understanding the changing competitive landscape
    • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
    • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
    • Examine the historical sales performance of a drug in seven major markets
    • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

    Table of Contents

    1. Table of Contents

    • 1.1 List of Tables
    • 1.2 List of Figures

    2. Introduction

    • 2.1 Schizophrenia
    • 2.2 Symptoms
    • 2.3 Schizophrenia Market
    • 2.4 Epidemiology
    • 2.5 Etiology
      • 2.5.1 Genetic Factors
      • 2.5.2 Environmental Factors
      • 2.5.3 Abnormal Brain Structure
    • 2.6 GlobalData Report Guidance

    3. Schizophrenia: Market Characterization

    • 3.1 Schizophrenia Market
    • 3.2 Schizophrenia Market Forecasts and CAGR
    • 3.3 Drivers of Schizophrenia Therapeutics Market
      • 3.3.1 Patent Expiry of Leading Marketed Drugs
      • 3.3.2 Increasing Patient Pool
      • 3.3.3 High Prescription Rates
      • 3.3.4 Low Patient Compliance Rate
      • 3.3.5 High Unmet Need

    4. Classification of Schizophrenia

    • 4.1 Age of Onset of Schizophrenia
      • 4.1.1 Pediatric / Adolescent / Childhood Schizophrenia
      • 4.1.2 Adult Schizophrenia
    • 4.2 Associated Symptoms
      • 4.2.1 Paranoid Schizophrenia
      • 4.2.2 Disorganized Schizophrenia
      • 4.2.3 Catatonic Schizophrenia
      • 4.2.4 Residual Schizophrenia
      • 4.2.5 Undifferentiated Disorder

    5. Treatment for Schizophrenia

    • 5.1 Crisis Resolution Teams (CRT)
    • 5.2 Voluntary and Compulsory Detention
    • 5.3 Antipsychotics
      • 5.3.1 Typical Antipsychotics
      • 5.3.2 Atypical Antipsychotics
      • 5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

    6. Cariprazine

    • 6.1 Introduction
    • 6.2 Mechanism of Action
    • 6.3 Clinical Studies
    • 6.4 Cariprazine Drug Development Status
    • 6.5 Factors Affecting Sales of Cariprazine
      • 6.5.1 Unique Receptor Binding Properties
      • 6.5.2 High Competition
      • 6.5.3 Collaborations
      • 6.5.4 Lack of Presence in EU
    • 6.6 Drug Evaluation
      • 6.6.1 Drug Risk Benefit Score
      • 6.6.2 Intensity of Competition
    • 6.7 Sales Forecasts
      • 6.7.1 Target Patient Pool of Cariprazine
      • 6.7.2 Dosing
      • 6.7.3 Market Penetration
      • 6.7.4 Annual Cost of Therapy
      • 6.7.5 Sales Projections of Cariprazine

    7. Schizophrenia Market: Appendix

    • 7.1 Market Definitions
    • 7.2 Abbreviations
    • 7.3 Research Methodology
    • 7.4 Drug Sales Estimates Model
    • 7.5 Contact Us
    • 7.6 Disclaimer
    • 7.7 Sources

    List of Tables

    • Table 1: Cariprazine, Phase IIb Clinical Trials Results
    • Table 2: Cariprazine, Drug Development Status, 2010
    • Table 3: Drug Risk Benefit Score of Cariprazine
    • Table 4: Competitors of Cariprazine
    • Table 5: Cariprazine, Schizophrenia, Global, Sales Forecasts ($m), 2013-2020
    • Table 6: Cariprazine, Schizophrenia, The US, Sales Forecasts ($m), 2013-2020
    • Table 7: Cariprazine, Schizophrenia, Japan, Sales Forecasts ($m), 2016-2020

    List of Figures

    • Figure 1: Risk of Developing Schizophrenia
    • Figure 2: Environmental Factors in the Development of Schizophrenia
    • Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 2010-2020
    • Figure 4: Classification of Schizophrenia based on the Age of Disease Onset
    • Figure 5: Reduction in PANSS Scores for Atypical Antipsychotics
    • Figure 6: Drug Model Diagram of Cariprazine
    • Figure 7: Cariprazine, Schizophrenia, Global, Sales Forecasts ($m), 2013-2020
    • Figure 8: Cariprazine, Schizophrenia, The US, Sales Forecasts ($m), 2013-2020
    • Figure 9: Cariprazine, Schizophrenia, Japan, Sales Forecasts ($m), 2016-2020
    • Figure 10: Cariprazine, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2020
    Back to Top